Navigation Links
Scripps Research wins more than $2 million to study prostate cancer
Date:4/26/2011

JUPITER, FL, April 26, 2011 The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

The five-year grant from the National Institutes of Health (NIH) will fund research to advance the development of novel therapeutic strategies for prostate cancer treatment and prevention.

"This new funding will help us continue our work into the origins of prostate cancer and the role that inflammation plays in its development," said Jun-Li Luo, PhD, an assistant professor on the Florida campus of Scripps Research and principal investigator for the new study. "We are pleased that Moffitt, one of the country's leading treatment and research centers, will be our partner in this research. Gaining a better understanding of the inflammatory process should help lay the foundation for developing novel therapeutic strategies for this disease."

"This collaboration with Scripps Florida is a great opportunity to help uncover the underlying mechanisms of prostate cancer," said Shohreh Dickinson, MD, an assistant professor at Moffitt, where scientists will study and interpret pathology slides of human cells as part of the new study. "It's also a great opportunity for two Florida research centers to advance the science that, hopefully, will one day help put an end to this terrible disease."

Prostate cancerwhich, according to the American Cancer Society, will affect one in six American men in their lifetimeis the second-leading cause of death after lung cancer in American men. Prostate cancer is driven by androgen, the male sex hormone, and androgen deprivation is considered a first-line treatment of the disease once it spreads beyond the prostate gland.

Eventually, all prostate cancer becomes resistant to the treatment, and the disease grows independently of androgen. This can occur almost anytime during treatment. Currently there are no effective treatments for what is known as hormone-refractory prostate cancer.

Luo's work has long been focused on the role of inflammation in cancer and the body's innate inflammatory response, which encourages tumor growth. In earlier studies, he found that blocking one of the factors involved in inflammationthe nuclear factor-kappa B (NF-kB)dramatically impaired development of the disease. In addition, Luo has identified tumor-infiltrating B cells as another critical component of the inflammatory response that enhances androgen-independent tumor growth.

The new study will further define how B cells control the spread of hormone refractory cancer.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. New lupus drug results from Scripps Research technology
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Scripps Research study points to liver, not brain, as origin of Alzheimers plaques
4. Scripps Research compound blocks brain cell destruction in Parkinsons disease
5. Scripps Research scientists develop powerful new methodology for stabilizing proteins
6. Scripps Research scientists find measles natural nemesis
7. Scripps Research scientists awarded $2.35 million to study new obesity treatment
8. Scripps Research scientists identify first synthetic activator of 2 critical proteins
9. Scripps Clinic nurse to receive 2010 ASTRO Nurse Excellence Award
10. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
11. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: